Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) shares hit a new 52-week low on Thursday. The company traded as low as $31.63 and last traded at $31.63, with a volume of 200 shares. The stock had previously closed at $35.50.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on ZLDPF. Zacks Research downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 10th. Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Finally, Barclays downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold”.
Read Our Latest Stock Report on Zealand Pharma A/S
Zealand Pharma A/S Stock Down 4.1%
The company has a market capitalization of $2.18 billion, a PE ratio of 5.28 and a beta of 0.99. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.98 and a current ratio of 13.98. The company’s 50-day moving average is $37.11 and its 200 day moving average is $45.65.
Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.57) by $1.45. The firm had revenue of $0.62 million for the quarter, compared to the consensus estimate of $1.33 million. Zealand Pharma A/S had a net margin of 67.13% and a return on equity of 19.70%. As a group, analysts anticipate that Zealand Pharma A/S will post 5.35 EPS for the current year.
About Zealand Pharma A/S
Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.
Further Reading
- Five stocks we like better than Zealand Pharma A/S
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
